title: Novel antiangiogenic therapies against advanced hepatocellular carcinoma (HCC).
abstract: Angiogenesis is a cornerstone in the process of hepatocarcinogenesis. In the sorafenib era, other antiangiogenic targeted drugs, such as monoclonal antibodies and a new generation of tyrosine kinase inhibitors, have been shown in phase II trials to be safe and effective in the treatment of advanced hepatocellular carcinoma. Several currently active phase III trials are testing these drugs, both in first- and second-line settings. Strategies to overcome primary and acquired resistance to antiangiogenic therapy are urgently needed. Novel biomarkers may help in improving the efficacy of drugs targeting angiogenesis.
authors.affiliation: Medical Oncology Department, Miguel Servet University Hospital, Zaragoza, Spain. rapazocid@seom.org
authors.forename: R A
authors.initials: RA
authors.lastname: Pazo-Cid
authors.forename: M
authors.initials: M
authors.lastname: Lanzuela
authors.forename: G
authors.initials: G
authors.lastname: Esquerdo
authors.forename: J L
authors.initials: JL
authors.lastname: Pérez-Gracia
authors.forename: A
authors.initials: A
authors.lastname: Antón
authors.forename: G
authors.initials: G
authors.lastname: Amigo
authors.forename: J Martínez
authors.initials: JM
authors.lastname: Trufero
authors.forename: A L
authors.initials: AL
authors.lastname: García-Otín
authors.forename: P
authors.initials: P
authors.lastname: Martín-Duque
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D006528:Carcinoma, Hepatocellular / Q000098:blood supply / Q000188:drug therapy*; D017326:Clinical Trials, Phase III as Topic; D006801:Humans; D008113:Liver Neoplasms / Q000098:blood supply / Q000188:drug therapy*; D009389:Neovascularization, Pathologic / Q000188:drug therapy; D009536:Niacinamide / Q000031:analogs & derivatives / Q000627:therapeutic use; D010671:Phenylurea Compounds / Q000627:therapeutic use; D000077157:Sorafenib
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D010671:Phenylurea Compounds; D009536:Niacinamide; D000077157:Sorafenib